Abstract

Objective: Targeting cancer-specific messenger RNAs (mRNAs) may offer novel insights into therapeutic strategies in osteosarcoma. This study aimed to discover possible osteosarcoma-specific mRNA and probe its biological functions.Methods: Based on mRNA-seq data from the TARGET database, stromal and immune scores were estimated for each osteosarcoma sample via the ESTIMATE algorithm. Stromal and immune mRNAs were obtained via integration of differentially expressed mRNAs between high and low stromal / immune score groups. Among hub and prognostic mRNAs, C3AR1 mRNA was focused and its prognostic value was assessed. The associations between C3AR1 mRNA and immune cells were analyzed via the CIBERSORT algorithm. Its expression was verified in osteosarcoma tissues and cells by RT-qPCR and western blot. The functions of C3AR1 were investigated by a series of experiments.Results: Low stromal and immune scores were both indicative of unfavorable outcomes for osteosarcoma patients. Eighty-eight up-regulated and seven down-regulated stromal and immune mRNAs were identified. Among 30 hub mRNAs, low expression of C3AR1 mRNA indicated worse outcomes than its high expression. There was a lower mRNA expression of C3AR1 in metastatic than non-metastatic osteosarcoma. C3AR1 mRNA was closely correlated to various immune cells such as macrophages. C3AR1 was verified to be down-regulated in osteosarcoma tissues and cells. Its overexpression suppressed proliferation, migration and invasion and induced apoptosis in osteosarcoma cells.Conclusion: C3AR1 mRNA could be a promising therapeutic target for osteosarcoma, linked with prognosis and tumor microenvironment.

Highlights

  • Osteosarcoma, as a common malignant bone cancer, is prevailing in childhood and adolescence [1]

  • C3AR1 messenger RNAs (mRNAs) was closely correlated to various immune cells such as macrophages

  • We found that C3AR1 mRNA could be a predictive factor for prognosis of osteosarcoma patients

Read more

Summary

Introduction

Osteosarcoma, as a common malignant bone cancer, is prevailing in childhood and adolescence [1]. The main treatment approaches are composed of neoadjuvant chemotherapy, surgery as well as adjuvant chemotherapy [3]. It remains unaltered for therapy and prognosis of osteosarcoma in the past 30 years. For advanced osteosarcoma, the effects of emerging therapies like targeted therapy and immunotherapy are unfavorable [4]. It is of significance for exploiting novel therapies or available signatures to prolong the survival time of osteosarcoma patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call